Kite’s CAR T-cell Therapy Yescarta Granted European Marketing Authorization for the Treatment of…
Kite, a Gilead Company announces that the European Commission (EC) has approved its CAR T-cell therapy Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with…
Read More...
Read More...